Immunomodulatory biomaterials : regulating the immune response with biomaterials to affect clinical outcome / edited by Stephen F. Badylak, Jennifer Elisseeff.

Format:

Book

Contributor:

Badylak, Stephen F., editor.

Elisseeff, Jennifer H., editor.

ScienceDirect (Online service)

Mary M. Kaufman Memorial Fund for Neuro-Science & Biomedical Engineering Source.

Series:

Woodhead Publishing series in biomaterials

Language:

English

Subjects (All):

Biomedical materials.

Immune response--Regulation.

Immune response.

Biological response modifiers.

Immunologic Factors.

Medical Subjects:

Immunologic Factors.

Physical Description:

1 online resource

Place of Publication:

Duxford : Woodhead Publishing, 2021.

Contents:

Intro

Immunomodulatory Biomaterials: Regulating the Immune Response with Biomaterials to Affect Clinical Outcome

Copyright

Contents

Contributors

Preface

Chapter 1: Engineering physical biomaterial properties to manipulate macrophage phenotype: From bench to bedside

1.1. Introduction

1.2. Role of macrophages in tissue repair and the foreign body response

1.3. Modulation of macrophage function via physical biomaterial properties in vitro

1.3.1. Stiffness

1.3.2. Topography or 3D architecture

1.3.3. Ligand presentation or geometry of adhesion

1.4. Macrophage response to implanted biomaterials in vivo

1.4.1. Non-degradable biomaterials

1.4.2. Degradable biomaterials

1.5. Clinical insight into the effect of physical biomaterial properties on macrophages during tissue repair

1.5.1. Dental implants

1.5.2. Wound dressings

1.5.3. Materials for cardiovascular repair

1.6. Conclusions and future directions

References

Chapter 2: Early factors in the immune response to biomaterials

2.1. Introduction

2.2. Protein adsorption

2.2.1. Complement cascade

2.2.2. Coagulation

2.2.3. Immunoglobulins

2.2.4. Innate immunity

2.2.4.1. Neutrophils

2.2.4.2. Mast cells

2.2.4.3. Macrophages/monocytes

2.2.5. Adaptive immunity

2.2.5.1. Dendritic cells

2.2.5.2. T Cells

2.2.5.3. B Cells

2.3. Foreign body giant cells

2.4. Fibrous capsule

2.5. Signaling pathways activated

2.5.1. TLRs and MyD88-dependent signaling

2.5.2. Inflammasome activation

2.5.3. JAK/STAT pathway

2.6. Conclusion

Chapter 3: Nanotechnology and biomaterials for immune modulation and monitoring

3.1. Introduction

3.2. Autoimmunity

3.3. Allergy

3.4. Transplant rejection

3.5. Clinical trials of tolerogenic nanotherapies

3.5.1. Liposomal.

3.5.2. Virus-like particles

3.5.3. Metallic

3.5.4. Polymeric

3.6. Precision diagnostics

3.6.1. Liquid biopsy

3.6.2. Immunological niches

3.7. Outlook and conclusion

Acknowledgments

Chapter 4: Immune-instructive materials and surfaces for medical applications

4.1. Introduction

4.1.1. Immune cells involved in inflammation

4.1.2. The foreign body response

4.2. Naturally occurring biomaterials with immune modulatory properties and their application in wound healing and reduct ...

4.3. Bioinstructive synthetic materials and their application in regenerative medicine

4.4. Developing ``immune-instructive´´ biomaterials

4.5. Concluding remarks

Chapter 5: Electrospun tissue regeneration biomaterials for immunomodulation

5.1. Introduction

5.2. Acknowledging immunomodulation in tissue engineering

5.3. Well-studied areas

5.3.1. Monocytes and macrophages

5.3.2. Platelets

5.4. Areas gaining attention

5.4.1. Neutrophils

5.4.2. Mast cells

5.5. Areas needing attention

5.5.1. Dendritic cells

5.5.2. Eosinophils

5.5.3. Basophils

5.5.4. Natural killer cells

5.5.5. T cells

5.5.6. B cells

5.6. Future directions

5.7. Conclusion

Chapter 6: Biomaterials and immunomodulation for spinal cord repair

6.1. Spinal cord injury

6.1.1. Acute phase of SCI

6.1.2. Subacute phase of SCI

6.1.3. Chronic phase of SCI

6.1.4. Self-repair after SCI

6.1.5. Translational potential of animal models of SCI

6.2. Immune response after SCI

6.3. Immunomodulation after spinal cord injury

6.4. Biomaterials for spinal cord repair

6.5. Immunomodulatory biomaterials for spinal cord injury

6.5.1. Immunomodulation by surface chemistry

6.5.2. Immunomodulation by topography

6.5.3. Immunomodulation by delivering agents.

6.5.3.1. Immunomodulation by providing biological ligands

6.5.3.2. Immunomodulation by delivering drugs

6.5.3.3. Immunomodulation by carrying cells

6.6. Natural immunomodulatory materials for spinal cord injury

6.7. Considerations and future directions

6.8. Conclusions and summary

Chapter 7: Biomaterial strategies to treat autoimmunity and unwanted immune responses to drugs and transplanted tissu

7.1. Introduction

7.1.1. Burden of disease

7.1.2. Current treatment options and challenges

7.1.3. Immunological causes of aberrant immune responses

7.1.3.1. Immunological basis for autoimmune diseases

7.1.3.2. Immunological basis for transplant rejection, anti-drug antibodies, and allergies

7.1.4. Antigen-specific tolerance as a treatment goal

7.2. Scope

7.3. Biomaterials in development for autoimmunity and anti-drug antibodies

7.3.1. Lessons from trials of free peptide and free protein

7.3.1.1. Type 1 diabetes

7.3.1.2. Multiple sclerosis

7.3.2. Antigen delivery vehicles without additional regulatory cues

7.3.2.1. Antigen depots

7.3.2.2. Nanoparticles

7.3.2.3. Alternative nanoparticle vehicles

7.3.2.4. Targeting liver APCs

7.3.2.5. Targeting splenic APCs

7.3.3. Antigen delivery vehicles with additional regulatory cues

7.3.3.1. Small molecule immunomodulators

7.3.3.2. Cytokines

7.3.4. Peptide-MHC complexes

7.3.4.1. Soluble pMHC complexes

7.3.4.2. Multimeric pMHC complexes

7.3.4.3. Nanoparticle pMHC complexes

7.4. Biomaterials in development for transplant tolerance

7.4.1. Transplant ECDI-treated cells

7.4.2. PLGA scaffold with transplanted cells and additional immunomodulatory drugs

7.5. Future of the field

7.5.1. Challenges and future directions

7.5.1.1. Standardization of immunological goals and readouts.

7.5.1.2. Further improvement in nanoparticle design

7.5.1.3. Manufacturability

7.5.2. Current or upcoming clinical trials

Chapter 8: Lipids as regulators of inflammation and tissue regeneration

8.1. Introduction

8.2. LC-MS based approaches to analyze lipids and their oxidation products

8.3. Free PUFA and their oxidation products as signals for immunomodulation and tissue regeneration

8.4. Oxidized phospholipids as modulators of the inflammatory response

8.5. Phospholipid signatures of EV

8.6. Hydrolysis of MBV derived oxygenated lipids and their possible role in inflammation and tissue regeneration

Chapter 9: Biomaterials modulation of the tumor immune environment for cancer immunotherapy

9.1. Introduction

9.2. Fundamentals of cancer immunology and immunotherapy

9.2.1. Cancer biology: Setting the stage

9.2.2. The role of immunity in cancer

9.3. Immunomodulatory biomaterials in cancer therapy

9.3.1. Cancer immunotherapy

9.3.2. Immunomodulatory biomaterials

9.3.3. Direct interactions between cancer and the biomaterial immune microenvironment

9.3.4. Biomaterial scaffold cancer vaccines

9.3.5. Biomaterial scaffolds for cell-based cancer immunotherapy

9.3.6. Immune tissue engineering

9.4. Summary

Chapter 10: Circumventing immune rejection and foreign body response to therapeutics of type 1 diabetes

10.1. Introduction

10.1.1. Type 1 diabetes (T1D)

10.1.2. Insulin and other injectable therapeutics

10.1.3. Biomaterials/devices

10.1.4. CGMs and insulin pumps

10.1.5. Cellular therapies

10.1.6. Protective immunity

10.2. Immune rejection for cells/grafts

10.2.1. General concepts for graft implementation

10.2.2. Transplant procedures

10.2.3. Human donor considerations

10.2.4. Alternative cell sources.

10.2.4.1. Xenogeneic grafts

10.2.4.2. Allogeneic grafts

10.2.4.3. Syngeneic grafts

10.2.4.4. Autologous grafts

10.3. Biological hurdles to preventing graft rejection

10.4. Advances in eliminating rejection of non-encapsulated grafts

10.4.1. Edmonton protocol and anti-inflammatory strategies

10.4.2. Delivery of antigen/nucleotide-based drugs for rejection suppression

10.4.3. Engineering therapeutic cells to modulate immune response

10.4.4. Tolerogenic vaccines

10.4.5. Artificial antigen-presenting cells for inducing tolerance

10.5. Advances in preventing FBR to bulk encapsulation systems

10.5.1. Bioresorption vs. lack of biodegradability

10.5.2. Non-biodegradable hydrogels/alginate and stable immune isolation

10.5.3. Effects of altering physical architecture

10.5.3.1. Size and shape

10.5.3.2. Surface topography and selective porosity

10.5.4. Chemical modification of material devices

10.5.4.1. Identification of anti-fibrotic chemistries: Surface vs. bulk modified

10.5.4.2. Zwitterionic (and other polymer-based) biocompatibility coatings

10.5.5. Long-term controlled release systems for rejection prevention

10.6. Pre/clinical observations, and models for translation

10.6.1. Choosing the right test animal and transplant site

10.6.2. Blood flow and nutrient considerations for graft viability

10.7. Future prospects and perceived challenges/difficulties

10.7.1. Increasing burdens on healthcare

10.7.2. Population expansion and increasing age of the general human populace

10.7.3. Increase in emerging diseases

10.8. Summary/conclusion

Chapter 11: Machine learning and mechanistic computational modeling of inflammation as tools for designing immuno

11.1. Biomaterials, inflammation, and wound healing.

Notes:

Electronic reproduction. Amsterdam Available via World Wide Web.

Print version record.

Local Notes:

Acquired for the Penn Libraries with assistance from the Mary M. Kaufman Memorial Fund for Neuro-Science & Biomedical Engineering Source.

Other Format:

Print version:

Print version : Immunomodulatory biomaterials.

ISBN:

9780128214565

0128214562

Publisher Number:

99993416260

Access Restriction:

Restricted for use by site license.